Swot Analysis Of Business Environment

1656 Words7 Pages

¬¬ INTERNATIONAL BUSINESS ENVIRONMENT
Individual Assignment

Know a Leading Business Enterprise and its Internal Environment

Declaration
I, Mohammad Farooq Shaik do hereby declare that the report is my individual effort and that no part of the report is copied from published/unpublished sources without proper citation.

Mohammad Farooq Shaik
PGP 30208
Section D

Table of contents

Executive Summary 3
Introduction 4
Vision and Mission 4
Management Structure and Nature 5
Human Resource 8
ENTERPRISE IMAGE AND BRAND EQUITY 9
Performance of the Enterprise 9
References 10

Executive Summary

This report studies the internal environment of GlaxoSmithKline (GSK). GSK is a pharmaceutical, vaccines, consumer healthcare, and biologics …show more content…

Over the years, the company went through some major mergers and acquisitions, transforming from Glaxo to Glaxo wellcome to GlaxoSmithKline. A final merger between Glaxo Wellcome and SmithKline Beecham in 2000 led to founding of GlaxoSmithKline. Considering the revenues as of March 14, 2014, GlaxoSmithKline was the 6th biggest pharmaceutical company in the world. [2] Moreover, as of May 2014, GSK boasted a market capitalization of £79 billion. With its corporate head office in London and operations in some 120 countries, GSK engages in creating, discovering, developing, manufacturing and marketing its consumer health-related and pharmaceutical products. It manufactures vaccines and drugs for diseases such as cancer, infections, asthma, diabetes and mental health conditions. GSK and its predecessor companies either discovered or developed many of these medicines, which are now sold as generics. GSK’s drugs and vaccines accounted for a revenue of £21.3 billion in 2013. [1] The consumer health section earned £5.2 billion in 2013. The consumer health care division comprises of oral healthcare and nutritional products such as Sensodyne, Horlicks and Boost. …show more content…

This makes it a tall hierarchy. At the top, GSK’s Board of Director comprises of 14 members, including the CEO. The CEO is assisted by a Corporate Executive Team of another 13 members, each of whom are responsible for specific part of the business. The CEO is responsible for the vision and mission. He drives the international growth and involves the R&D division.

The Chairman leads and manages the business of the board. He/she provides the focus and direction and ensures proper functioning of the Board and its Committees. He sets the agenda for the Board meetings to promote constructive decision-making process and communicates with the Board members regularly to update them with the company’s

Open Document